Innovation Takes All of Us

Niels Emmerich, Vice President, Global Head Search & Evaluation and Global Alliances
Debra Chao, Senior Director, Oncology
Murali Gopalakrishnan, Senior Director, Neuroscience
Rohun Palekar, Director, Specialty
Arpita Maiti, Vice President, Immunology, Specialty and Discovery Platforms S&E
Douglas Faunce, Executive Director, Eye Care
Chinmay Kanuga, Senior Director, Allergan Aesthetics and Operations
Joachim Vogt, Director, Western Europe
Sergio Capancioni, Director, Western Europe
Wendy Tai, Director, Japan/Asia/Pacific

Jay Stamatis, Vice President, Head Business Development & Acquisitions
Rachel Strick, Vice President, Immunology, Specialty and Discovery Platforms BD&A
Rahul Jerath, Senior Director, Oncology
Tony Brazda, Senior Director, Neuroscience
David Moss, Associate VP, Eye Care
John FitzGerald, Senior Director, Specialty, Outlicensing
Sridhar Mandapati, Senior Director, International Business Development
Daliana Mauch, Director, Allergan Aesthetics

Jonathan Kern, Vice President, Global Alliances
Jason Powell, Senior Director, Enterprise Partnerships
Shankar Subramanian, Senior Director, Specialty & Academic Partnerships
Sebastian Espinosa, Senior Director, Oncology
Amy Smith-Gibbons, Senior Director, Oncology
Rajiv Janjikhel, Senior Director, Neuroscience, Eye Care
John Larson, Senior Director, Immunology, Mature Products
Allison Hoch, Director, Neuroscience, Eye Care, Immunology
Melanie Patterson, Director, Neuroscience
Amanda McAllister, Director, Discovery Platforms, Allergan Aesthetics, Neurotoxins
Cardine Nokwe, Director, Immunology, Specialty

Christian Schubert, Vice President and Head, Boston / Cambridge area
Doug Faunce, Executive Director, Irvine area
Shawna Frazier, Director, San Francisco area
Donmienne Leung, Director, Oxford area
Claire Leurent, Senior Director, Cambridge area
Danjuma Quarless, Associate Director, San Francisco area
Joachim Vogt, Director, Ludwigshafen area
Christina Vorvis, Director, Boston / Cambridge area
Shann Yu, Associate Director, Boston / Cambridge area

As leading experts in autoimmune diseases and therapies, AbbVie is focused on developing new medicines to address chronic progressive diseases in the field of immunology. Our programs focus on investigating both targeted oral therapies and biologics. Our areas of interest include:

• Gastroenterology (Crohn’s disease, ulcerative colitis)
• Dermatology (psoriasis, atopic dermatitis, hidradenitis suppurativa)
• Rheumatology (RA, PsA, AS, GCA, PMR)
• Innate immunity / interferon and TH2 mediated diseases (SLE, systemic sclerosis, Sjögren’s syndrome, DM, eosinophilic diseases)
• Select fibrotic conditions (systemic sclerosis, IPF)

Our goal is to transform the way cancer is treated. AbbVie is committed to discovering and developing therapies that work against the processes that cancer cells need to survive. We are committed to achieving long-term control of hematologic malignancies, and investing to identify and advance promising therapies for solid tumors. Our areas of interest include:

• Novel and differentiated programs directed towards enhanced tumor cell targeting, oncogenic signaling pathways and immuno-oncology
• Targeted biologics and next generation in vivo cell therapies
• Novel approaches to small molecules, including technologies to address hard-to-drug target classes
• Ovarian cancer, Gastrointestinal Cancers (CRC, GEA, PDAC), and Lung Cancer (NSCLC, SCLC)
• Hematological Malignancies (CLL, MM, NHL, AML)

Our commitment to preserving the personhood of those living with neurological and psychiatric disorders is unwavering. AbbVie Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders with high unmet need. Our areas of interest include:

• Disease modification approaches for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, and select diseases driven by shared biological pathways
• Psychiatric diseases, including  bipolar disorder, bipolar depression, major depressive disorder, generalized anxiety disorder and schizophrenia
• Symptomatic approaches with clinical validation for cognitive and neurobehavioral deficits in Alzheimer’s and Parkinson’s disease
• Migraine
• Spasticity and movement disorders; neurorestoration in multiple sclerosis

Our mission in eye care remains to protect and preserve vision for a better quality of life for the millions of people who experience vision loss every year. AbbVie continues to search for new therapeutics that address unmet needs and new approaches to retina-related diseases, glaucoma, dry eye disease, and refractive conditions. We are focused on both biologics and small molecules, as well as next generation drug delivery technologies. Our areas of interest include:

• Retinal degeneration, including Dry AMD/geographic atrophy, Wet AMD and diabetic retinal diseases
• Dry eye and ocular surface disease of various etiologies
• Glaucoma, addressing intraocular pressure control and neuroprotection
• Refractive medicine, including presbyopia, myopia and corneal dystrophies

Allergan Aesthetics is developing a portfolio of innovative products in the areas of facial and body filling, breast reconstruction/augmentation, and regenerative soft tissue repair. We are interested in strategic collaborations that broaden our understanding of the aging process, and therapeutic  targets to address the natural, physical, and biological changes that occur with age. We seek out and partner with strategic collaborators for neurotoxins, dermal fillers, body aesthetics, plastic surgery and regenerative medicine, hair growth, and skin care. We are also interested in exploring the use of energy-based devices for the field of body aesthetics. Cell and gene therapies with a focus on extracellular matrix components including collagen and elastin are also of interest. Our areas of interest include:

• Dermal injectables for skin and tissue
• Plastics and regenerative medicine
• Toxins for aesthetic and therapeutics
• Hair growth
• Body contouring and fat reduction
• Topical skin care

We also selectively focus our attention on other areas where there is unmet need:

• Virology
• Cystic fibrosis
• Women’s health
• Platforms and technologies